Long-term Stability and in Vitro Release of HPTH(1-34) from a Multi-reservoir Array

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2008 Feb 13

PMID 18266089

Citations 7

Authors

Elizabeth R Proos

James H Prescott

Mark A Staples

Affiliations

Soon will be listed here.

Abstract

Purpose: Therapeutic peptides generally exhibit poor oral bioavailability and require alternative methods of delivery. Implanted microelectromechanical systems-based multi-reservoir devices enable programmable, chronic, pulsatile peptide delivery. This report describes parathyroid hormone fragment (hPTH (1-34)) formulations suitable for delivery from a multi-reservoir array.

Methods: The stability of hPTH(1-34) lyophilizates obtained from aqueous acidic solutions was assessed by reverse phase high pressure liquid chromatography. An in vitro test device measured in vitro release kinetics.

Results: Novel, highly concentrated (>50 mg/mL) hPTH(1-34) solutions were dispensed as bulk samples (1-3 mg peptide) in vials and as individual doses (13-21 microg peptide) in reservoir arrays. Bulk and array samples were lyophilized and stored at 37 degrees C. Bulk lyophilizate hPTH(1-34) purity after lyophilization, after 8 weeks, and after 26 weeks exceeded 96%, 90%, and 80%, respectively. The hPTH(1-34) stored in multi-reservoir arrays exhibited similar purity over 29 weeks at 37 degrees C. Initially and over 29 weeks, over half of the peptide was consistently released from arrays into neutral, isotonic solution in less than 30 min with quantitative recoveries (>95%) within 3 h.

Conclusions: Clinically relevant formulations of hPTH(1-34) for use with implantable multi-reservoir devices are achievable.

Citing Articles

Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications.

Villarruel Mendoza L, Scilletta N, Bellino M, Federico Desimone M, Catalano P Front Bioeng Biotechnol. 2020; 8:827.

PMID: 32850709 PMC: 7405504. DOI: 10.3389/fbioe.2020.00827.

On-demand antibiotic-eluting microchip for implanted spinal screws.

Eltorai A J Orthop. 2017; 14(4):565-570.

PMID: 28878518 PMC: 5577398. DOI: 10.1016/j.jor.2017.07.012.

Microchips in Medicine: Current and Future Applications.

Eltorai A, Fox H, McGurrin E, Guang S Biomed Res Int. 2016; 2016:1743472.

PMID: 27376079 PMC: 4914739. DOI: 10.1155/2016/1743472.

Influence of Parathyroid Hormone-Loaded PLGA Nanoparticles in Porous Scaffolds for Bone Regeneration.

Gentile P, Nandagiri V, Pabari R, Daly J, Tonda-Turo C, Ciardelli G Int J Mol Sci. 2015; 16(9):20492-510.

PMID: 26343649 PMC: 4613215. DOI: 10.3390/ijms160920492.

Microelectromechanical systems and nephrology: the next frontier in renal replacement technology.

Kim S, Roy S Adv Chronic Kidney Dis. 2013; 20(6):516-35.

PMID: 24206604 PMC: 3866020. DOI: 10.1053/j.ackd.2013.08.006.

References

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

Frolik C, Black E, Cain R, Satterwhite J, Brown-Augsburger P, Sato M . Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone. 2003; 33(3):372-9. DOI: 10.1016/s8756-3282(03)00202-3. View

Keutmann H, Hendy G, Boehnert M, ORIORDAN J, Potts Jr J . Purification of human parathyroid hormone: recent studies and further observations. J Endocrinol. 1978; 78(1):49-58. DOI: 10.1677/joe.0.0780049. View

Prescott J, Krieger T, Lipka S, Staples M . Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multi-reservoir array. Pharm Res. 2007; 24(7):1252-61. DOI: 10.1007/s11095-007-9243-2. View

Hock J, Gera I . Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res. 1992; 7(1):65-72. DOI: 10.1002/jbmr.5650070110. View

Suzuki Y, Nagase Y, Iga K, Kawase M, Oka M, Yanai S . Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1-34). J Pharm Sci. 2002; 91(2):350-61. DOI: 10.1002/jps.10019. View

Codrons V, Vanderbist F, Verbeeck R, Arras M, Lison D, Preat V . Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci. 2003; 92(5):938-50. DOI: 10.1002/jps.10346. View

Tregear G, Van Rietschoten J, Greene E, Niall H, Keutmann H, Parsons J . Solid-phase synthesis of the biologically active N-terminal 1 - 34 peptide of human parathyroid hormone. Hoppe Seylers Z Physiol Chem. 1974; 355(4):415-21. DOI: 10.1515/bchm2.1974.355.1.415. View

Stratton L, Kelly R, Rowe J, Shively J, Smith D, Carpenter J . Controlling deamidation rates in a model peptide: effects of temperature, peptide concentration, and additives. J Pharm Sci. 2001; 90(12):2141-8. DOI: 10.1002/jps.1165. View

10.

Leone-Bay A, Sato M, Paton D, Hunt A, Sarubbi D, Carozza M . Oral delivery of biologically active parathyroid hormone. Pharm Res. 2001; 18(7):964-70. DOI: 10.1023/a:1010936227570. View

11.

Hamdy R . Osteoporosis, the deafening silent epidemic. South Med J. 2002; 95(6):567-8. DOI: 10.1097/00007611-200206000-00001. View

12.

Dobnig H, Turner R . The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997; 138(11):4607-12. DOI: 10.1210/endo.138.11.5505. View

13.

Kamberi M, Chung P, DeVas R, Li L, Li Z, Ma X . Analysis of non-covalent aggregation of synthetic hPTH (1-34) by size-exclusion chromatography and the importance of suppression of non-specific interactions for a precise quantitation. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 810(1):151-5. DOI: 10.1016/j.jchromb.2004.07.026. View

14.

Wang W . Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000; 203(1-2):1-60. DOI: 10.1016/s0378-5173(00)00423-3. View

15.

Jerome C, Burr D, Van Bibber T, Hock J, Brommage R . Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone. 2001; 28(2):150-9. DOI: 10.1016/s8756-3282(00)00430-0. View

16.

Andya J, Maa Y, Costantino H, Nguyen P, Dasovich N, Sweeney T . The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm Res. 1999; 16(3):350-8. DOI: 10.1023/a:1018805232453. View

17.

Yang M, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S . Crystalline monoclonal antibodies for subcutaneous delivery. Proc Natl Acad Sci U S A. 2003; 100(12):6934-9. PMC: 165808. DOI: 10.1073/pnas.1131899100. View

18.

Potts Jr J, Tregear G, Keutmann H, Niall H, Sauer R, Deftos L . Synthesis of a biologically active N-terminal tetratriacontapeptide of parathyroid hormone. Proc Natl Acad Sci U S A. 1971; 68(1):63-7. PMC: 391103. DOI: 10.1073/pnas.68.1.63. View

19.

Fraenkel L, Gulanski B, Wittink D . Patient willingness to take teriparatide. Patient Educ Couns. 2006; 65(2):237-44. PMC: 1769517. DOI: 10.1016/j.pec.2006.08.004. View

20.

Agu R, Valiveti S, Earles D, Klausner M, Hayden P, Wermeling D . Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. Endocr Res. 2004; 30(3):455-67. DOI: 10.1081/erc-200035957. View